Human retroviruses after 20 years: A perspective from the past and prospects for their future control

Immunological Reviews

Volumn 185, Issue , 2002, Pages 236-265

  Gallo, Robert C ^a,b  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

^b UNIVERSITY OF BALTIMORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL DNA; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; BREAST FEEDING; BYSTANDER EFFECT; CARCINOGENESIS; CELL CONTACT; CELL DEATH; CELL MATURATION; CLONAL ANERGY; EDUCATION; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; HUMORAL IMMUNITY; IMMUNE SYSTEM; LEUKEMIA; LYMPHOCYTE PROLIFERATION; MOLECULAR BIOLOGY; NEUROLOGIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROVIRUS; RETROVIRUS; REVIEW; T LYMPHOCYTE; TARGET CELL; TIME; VIRION; VIROGENESIS; VIRUS REPLICATION; VIRUS SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; HIV; HIV ENVELOPE PROTEIN GP120; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS;

EID: 0036630405     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18520.x     Document Type: Review

References (258)

1. RNA-dependent DNA polymerase in virions of Rous sarcoma virus
2. RNA-dependent DNA polymerase in virions of RNA tumour viruses
3. Reverse transcriptase activity of human acute leukemic cells. Purification of the enzyme, response to AMV 70S RNA, and characterization of the DNA product
4. DNA-dependent DNA polymerase I and II from normal human-blood lymphocytes
5. Stimulated normal human lymphocytes contain a ribonuclease-sensitive DNA polymerase distinct from viral RNA-directed DNA polymerase
6. Purification, characterization, and comparison of the DNA polymerases from two primate RNA tumor viruses
7. DNA polymerases of normal and neoplatic mammalian cells
8. DNA-directed and RNA-primed DNA synthesis in microsomal and mitochondrial fractions of normal human lymphocytes
9. Serologic analysis of human deoxyribonucleic acid polymerases
10. Serological analysis of cellular and viral DNA polymerases by an antiserum of DNA polymerase ã of human lymphoblasts
11. In vitro control of the development of macrophage and granulocyte colonies
12. Studies on colony formation in vitro by mouse bone marrow cells. I. Continuous cluster formation and relation of clusters to colonies
13. Long-term suspension cultures of human cord blood myeloid cells
14. Human hematopoietic cells a search for retrovirus-related information in primary tissues and development of liquid suspension culture systems for studies of cell growth and differentiation and of virus-cell interactions
15. Selective in vitro growth of T lymphocytes from normal human bone marrows
16. Functional and morphologic characterization of human T cells continuously grown in vitro
17. Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media
18. Detection and isolation of type C retrovirus particles from fresh and cultured lumphocytes of a patient with cutaneous T-cell lymphoma
19. Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line
20. Immunological properties of a type C retrovirus isolated from cultured human T-lymphoma cells and comparison to other mammalian retroviruses
21. Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes
22. Antibodies in human sera reactive against an internal structural protein of human T-cell lymphoma virus
23. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukemia
24. Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody
25. Adult T cell leukemia in Japan
26. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies of die antigen in human sera
27. The virus of Japanese adult T-cell leukaemia is a member of the human T-cell leukaemia virus group
28. Adult T-cell lymphoma-leukaemia in blacks from the West Indies
29. Human T-cell leukemia virus in immigrants to the United Kingdom
30. The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma
31. Retroviruses
32. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia
33. Antibodies of human T-lymphotropic virus type-I in patients with tropical spastic paraparesis
34. Chronic progressive myelopathy associated with elevated antibodies of human T-lymphotropic virus type I and adult T-cell leukemia like cells
35. Type C virus particles in a cord T-cell line derived by co-cultivatingnormal human cord leukocytes and human leukaemic T cells
36. Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus
37. Human T-lymphotropic retroviruses
38. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control
39. Molecular cloning of the provirus DNA and the unique terminal structure
40. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1
41. Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth
42. Activation of NF-kappa B/Rel by Tax involves degraduation of I kappa B alpha and is blocked by a proteasome inhibitor
43. Transcriptional activator Tax of HTLV-1 binds to the NF-kappa B precursor p105
44. Human T-cell lymphotropic virus type I (HTLV-1) transcriptional activator, tax, enhances CREB binding to HTLV-I 21-based-pair repeats by protein-protein interaction
45. HTLV-I trans-activator protein, tax is a trans-repressor of the human beta-polymerase gene
46. Down-regulation of the INK4 family of cyclin-dependent kinase inhibitors by tax protein of HTLV1 through two distinct mechanisms
47. Clastogenic effect of the human T-cell leukemia virus type I tax oncoprotein correlates with unstablized DNA breaks
48. Immunopathogenesis of HTLV-I-associated myelopathy/tropical spastic paraparesis
49. Human T-lymphotropic viruses. HTLV-1 and HTLV-II
50. Human T-lymphotropic virus type-1 infected T lymphocytes impair catabolism and uptake of glutamate by astrocytes via tax-1 and tumor necrosis factor alpha
51. How does interleukin-15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis?
52. + T cells
53. The path to the discoveries of human retroviruses
54. Pathogenesis of disease induced by human lymphotropic virus type I infection
55. Epidemiology of the acquired immunodeficiency syndrome
56. Alternation of T-cell functions by infection with HTLV-1 and HTLV-II
57. Reactivity of HTLV-transformed human T-cell lines of MHC class II antigens
58. The AIDS virus
59. Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS
60. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome AIDS
61. A new human T-lymphotropic retrovirus. Characterization and possible role in lymphadenopathy and immune deficiency syndromes
62. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
63. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
64. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS
65. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS
66. Seroepidemiological studies of human T-lymphotropic type III in acquired immunodeficiency syndrome
67. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS
68. 3′-Azido-3′-deoxythymidine (BW A509U): An Antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro
69. Complete nucleotide sequence of the AIDS virus, HTLV-III
70. Nucleotide sequence of the AIDS virus, LAV
71. Nucelotide sequence and expression of an AIDS-associated retrovirus (ARV-2)
72. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS
73. A molecular clone of HTLV-III with biological activity
74. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III)
75. Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus
76. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells
77. The pX protein of HTLV-1 is a transcriptional activator of its long terminal repeat
78. Transcriptional activator protein encoded by the x-lor region of the human T-cell leukemia virus
79. Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat
80. Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III
81. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome
82. Genomic diversity of human T-lymphotropic virus type III (HTLV-III)
83. Low prevalence in the UK of HTLV-I and HTLV-II infection in subjects with AIDS, with extended lymphadenopathy, and at risk of AIDS
84. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
85. HTLV-III infection in brains of children and adults with AIDS encephalopathy
86. HTVL-III in cells cultured from semen of two patients with AIDS
87. HTLV-III in the semen and blood of a healthy homosexual man
88. The role of mononuclear phagocytes in HTLV-III/LAV infection
89. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques
90. The role for nonhuman primate models in the development and testing of AIDS vaccines
91. Sequence analysis of original HIV-1
92. LAV revisited: Origins of the early HIV-1 isolates from Institut Pasteur
93. Genomic diversity of human T-lymphotropic virus type III (HTLV-III)
94. Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III. Different viruses exhibit greatest divergence in their envelope genes
95. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome
96. Genomic variation of HTLV-III/LAV, the retrovirus of AIDS
97. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays
98. Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter- proximal transcripts
99. Quanitification of latent tissue reservoirs and total body viral load in HIV-1 infection
100. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
101. + T cells during primary HIV-1 infection
102. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation
103. Charting HIV's remarkable voyage through the cell: Basic science as a passport for future therapy
104. In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates
105. Infection of natural killer cells by human herpesvirus 6
106. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy
107. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
108. Natural history of HIV-1 viremia after seroconversion and proximal to AIDS in a large cohort
109. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study
110. CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication
111. Chemokine receptors as HIV-1 coreceptors roles in viral entry, tropism, and disease
112. Inhibition of HIV-1 infection by the α-chemokine MDC
113. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS
114. C-C chemokines, pivotal in protection against HIV type 1 infection
115. +) lymphocytes from exposed-uninfected individuals: Association with long expression of CCR5 and high production of beta-chemokines
116. + T cells are associated with asymptomatic HIV-1 infection
117. Spontaneous and antigen-induced production of HIV-inhibitory b-chemokines are associated with AIDS-free status
118. HIV pathogenesis: Mechanisms of susceptibility and disease progression
119. Long-term cultures of HTLV-III infected T cells. A model of cytopathology of T-cell depletion in AIDS
120. Immunopathogenesis of HIV infection
121. Immune activation correlates better than HIV plasma viral load with CD4 T-cell decline during HIV infection
122. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
123. Increased CCR5 and CXCR4 expression in Ethiopians in Israel: Environmental and constitutive factors
124. Quantitative image analysis of HIV-1 infection in lymphoid tissue
125. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
126. Whole body positron emission tomography imaging of activated lymphoid tissues during acute SHIV89.6PD infection in rhesus macaques
127. Virus isolation from and identification of HTLV-III/LAV producing cells in brain tissue from an AIDS patient
128. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization
129. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: Evidence for viral replication in all stages of HIV disease
130. Quantitation of HIV-1 in blood of infected persons
131. Frequent detection of HIV-1 specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease
132. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
133. Evidence of a process of death of lymphocytes by apoptosis in patients infected with HIV
134. Apoptosis as a mechanism of cell death in cultured T lymphoblasts acutely infected with HIV-1
135. Accelerated apoptosis in peripheral blood mononuclear cells from HIV-1 infected patients and in CD cross linked PBMCs from normal individuals
136. Role of apoptosis in HIV disease pathogenesis
137. Lymphadenopathy associated virus. Infection of a blood donor-recipient pair with Acquired Immunodeficiency Syndrome
138. Indirect mechanisms of HIV pathogenesis: How does HIV kill T-cells?
139. Aopotosis occurs predominantly in bystander cells and not in productively infected cells of HIV and SIV infected lymph nodes
140. Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes
141. + T lymphocytes from HIV-infected individuals is mediated by FasL and Tumor Necrosis Factor
142. Upregulation of Fas Ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes
143. The expression of Fas ligand by macrophages and its upregulation by Human Immunodeficiency Virus infection
144. CD8 naïve T cell counts decrease progressively in HIV-infected adults
145. HIV infection of human bone marrow stromal fibroblasts
146. Tat protein stimulates production of transforming growth factor-α1 by marrow macrophages: A potential mechanism for human immunodeficiency virus-1-induced hematopoietic suppression
147. Replication of the human immunodeficiency virus 1 and impaired differentiation of T cells after in vitro infection of bone marrow immature T cells
148. + bone marrow cells are infected with HIV in a subset of seropositive individuals
149. Infection and replication of HIV-1 of purified progenitor cells of normal human bone marrow
150. In vitro human immunodeficiency virus-1 infection purified hematopoietic progenitors single-cell culture
151. + T-cell depletion in HIV disease
152. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection
153. Evidence for increased T cell turnover and decreased thymic output in HIV infection
154. HIV in the developing world
155. Differential ability of T cell subsets to undergo activation-induced cell death
156. Viral DNA carried by human immunodeficiency virus type 1 virions
157. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
158. Establishment of a functional human immunodeficiency virus type-1 (HIV-1) reverse transcription complex involves the cytoskeleton
159. Inhibition of human immunodeficiency virus syncytium formation and virus replication castanospermine
160. Molecular determinants of acute single-cell lysis by human immunodeficiency virus Type 1
161. Importance of membrane fusion mediated by the human immunodeficiency virus envelope glycoproteins for lysis of primary CD-4 positive T Cells
162. + T-lymphocyte depletion in simian-human immunodeficiency virus-infected macaques
163. + T-cell depletion in macaques infected by a simian-human immunodeficiency virus
164. Sensitization of T-cells to CD95 mediated apoptosis by HIV-1 tat and gp120
165. Tat as one key to HIV-induced immune pathogenesis and as an important component of a vaccine
166. Apoptosis enhancement by the HIV-1 Nef protein
167. HIV-1 Nef inhibits ASK-1 dependent death signalling providing a potential mechanism for protecting the infected host cell
168. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection
169. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr
170. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition
171. Lentivirus replication and regulation
172. Structure, splicing and regulation of exression of lentiviruses and other complex retroviruses
173. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
174. HIV-1 auxiliary proteins: Making connections in a dying cell
175. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo
176. The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2+ M phase of the cell cycle
177. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection
178. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest
179. Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells
180. An examination of signs of disease progression in survivors of the Sydney blood bank cohort
181. +) T-cell depletion in human lymphoid tissue ex vivo
182. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner
183. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
184. Human immunodeficiency virus type 1 nef selectively associates with a catalytically active subpopulation of p21-activated kinase2 (PAK2) independently of PAK2 binding to NcK or α-PIX
185. Evasion of cytotoxic T lymphocyte (CTL) responses by Nef-dependent induction of Fas Ligand (CD95L) expression of Simian Immunodeficiency Virus-infected cells
186. Induction of Fas Ligand expression by HIV involved the interaction of Nef with the T cell receptor ζ chain
187. Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine (Perspective)
188. Distinct mechansms trigger apoptosis in human immunodeficiency virus type-1 infected and in uninfected bystander T lymphocytes
189. + T cell hyperactivation and HIV type 1 replication
190. HIV-1 Tat protein mimicry of chemokines
191. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): A possible mechanism for Tat's immunosuppressive activity
192. Tat protein of human immunodeficiency virust type 1 induces interleukin-10 in human peripheral blood monocytes: Implication of protein kinase C-dependent pathway
193. HIV type 1 Tat protein inhibits interleukin 12 production by human peripheral blood mononuclear cells
194. Ultrastructural markers in AIDS
195. Critical role of Tat and IFNα in the HIV-1 induced immunosuppression leading to AIDS
196. Recombinant INF-α (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells
197. + T cells
198. Interferon α and Tat involvement in the immunosuppression of uninfected cells and C-C chemokine decline in AIDS
199. + T cells
200. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
201. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi sarcoma lesions of AIDS patients
202. Domains in the SPT5 protein that modulate its transcriptional regulatory properties
203. Tat is required for efficient HIV-1 reverse transcription
204. Functional domains of Tat required for efficient HIV-1 reverse transcription
205. +) cells purified from bone marrow of AIDS patients are committed to apoptotic cell death in culture
206. The enigmas of Kaposi's sarcoma
207. Human herpes virus-8 and HIV
208. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
209. Protease inhibitor resistant HIV-1 has marked decreased fitness in vivo
210. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
211. Differential HIV suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes
212. Beta chemokines and protection from HIV type 1 disease
213. + T cells are associated with asymptomatic HIV-1 infection
214. The potential for HIV fusion inhibition
215. Current evidence and future directions for targeting HIV entry
216. HIV-1 membrane fusion mechanism structural studies of the interactions between biologically-active peptides from gp41
217. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41 mediated virus entry
218. Human immunodeficiency virus Type 1 entry inhibitors PRO542 and T20 are potentially synergistic in blocking virus cell and cell-cell fusion
219. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
220. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
221. Expression and characterization of a single chain polypeptide analogue of the HIV-1 gp120-CD4 receptor complex
222. Expression and characterization of CD4-IgG2, a novel heterotetramer, that neutralizes primary HIV type 1 isolates
223. Prospects for the control of AIDS by immunizing seropositive individuals
224. A phase 1 evaluation of safety and immunogenicity of vaccination with recombinant gp160 in patients with early HIV infection
225. Immunotherapeutic strategies in the treatment of HIV infection and AIDS
226. Toward a new generation of vaccines: The anti-cytokine therapeutic vaccines
227. A randomized, placedo-controlled, blind anti-AIDS clinical trial: Safety and immunogenicity of a specific anti-IFN-α immunization
228. Anti-alpha interferon immunization: Safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression
229. Biological effect of active anti-IFN-α immunization in HIV-infected patients
230. Absence of clinical virological and immunological signs of progression in HIV-1 infected patients receiving active anti-alpha interferon immunization: A 30 month follow-up report
231. Safety and immunogenicity of HIV-1 tax toxoid in immunocompromised HIV-1-infected patients
232. Tat toxiod as a component of a preventive vaccine in seronegative subjects
233. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous tax toxoid
234. Inhibition of HIV-1 infection by the β-chemokine MDC
235. Protective effects on a live attenuated SIV vaccine with a deletion in the nef gene
236. Importance of the nef gene for maintenance of high virus loads and for development of AIDS
237. Pathogenicity of live attenuated SIV after mucosal infection of neonatal macagues
238. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
239. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
240. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
241. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
242. Repeated exposure of rhesus macaques to low doses of SIV did not protect them against the consequences of a high dose SIV challenge
243. Cellular immune response to SIVmac and HIV-2 in macaques: Model for the human HIV-1 infection
244. Structure of an HIV gp-120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
245. Cross clade neutralization of primary isolates of HIV-1 by human monoclonal antibodies and tetrameric CD4-IgG
246. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp 120 and gp 41 subunits is an antigenic mimic of the trimeric virion-associated structure
247. Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
248. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing response that includes antibodies selective for primary virus isolates
249. AIDS vaccines: On the trail of two trials
250. Strategies for designing and optimizing new generation vaccines
251. Improbability of effective vaccination against HIV because of its intracellular transmission and rectal portal entry
252. Sam68, RNA helicase A and Tap cooperate in the post-transcriptional regulation of HIV and type D retrovirus mRNA
253. Identification of a novel post-transcriptional regulatory element by using a rev and RRE-mutated HIV-1 DNA proviral clone as a molecular trap